StockWatch
·

Orchid Pharma Ltd Q2 FY27 Results

ORCHPHARMAQ2 FY27 Results
Filing
Result:Good#Turnaround#Margin expansion#Cost led

Beat/Miss: Inline

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue341.2712.2%76.3%
Total Income359.0217.3%75.7%
Expenditure332.199.5%60.0%
PBT26.84912.9%904.7%
Net Profit28.59786.8%599.6%
OPM7.07%2.47pp7.83pp
NPM7.96%6.91pp10.76pp
EPS4.77783.3%322.1%
View full financials

Core revenue grew 14.3% YoY with margin expansion (NPM -2.8%→8.0%) on opex discipline rather than one-offs, a clean loss-to-profit turnaround that came in-range/in-line vs street rather than a beat, keeping it in the good band.

Q2 FY-2027 RESULTS · ORCHPHARMA

Orchid Pharma turns profitable in Q2 FY27, consolidated PAT ₹28.6 Cr, revenue up 14% YoY

revenue +14.3% · margins expanding · inline vs street

14 Nov 2026 · 3 min read
Revenue

₹341.27 Cr

+14.3% YoY

PAT (consolidated)

₹28.59 Cr

Net margin

7.96%

+10.8pp YoY

EPS

₹4.77

Orchid Pharma's first full quarter since the Dhanuka Laboratories amalgamation shows a clean turnaround: consolidated PAT was ₹28.6 Cr in Q2 FY27 against a restated loss of ₹0.9 Cr in Q2 FY26, on revenue of ₹341.3 Cr, up 14.3% year-on-year and 12.2% sequentially from Q1 FY27's ₹304.2 Cr. Consolidated EPS was ₹4.77 (not annualised). Standalone — where the merged Dhanuka business itself sits — was stronger still, with PAT of ₹36.8 Cr (EPS ₹6.14) on the same ₹341.3 Cr revenue base; the ~₹8.2 Cr gap to consolidated PAT is a >20% divergence driven by loss-making US subsidiaries, worth flagging since readers will see both numbers.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹341.27 Cr+12.2%+76.3%
Expenses₹332.19 Cr+9.5%+60%
PAT₹28.59 Cr+786.8%—
Net margin7.96%+6.9pp+10.8pp
EPS₹4.77+783.3%+322.1%

Margins expanded on both counts: consolidated NPM rose to roughly 8.4% from -2.8% a year ago and about 1.1% last quarter, while EBITDA-level operating margin improved to around 7.1% from -0.8% YoY and 4.6% QoQ. The improvement sits mainly on the operating cost lines, which grew slower than revenue, with no exceptional item in this quarter (FY26's one-off was a ₹7.33 Cr labour-code provision booked only in the full-year column). Consolidated PAT also carries a ₹1.71 Cr profit share from associate Orbion Pharmaceuticals, versus a ₹2.39 Cr loss-share a year ago; stripping that out, core consolidated profit before associates was ₹26.9 Cr.

₹
783.69873.23962.781,052.321,141.86884.408-1109-0209-2510-2111-1211-13
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹884.4, down 6.4% over the past month of trading.

₹ Cr
-17.56-0.5316.533.5314.91Q1 FY26rev ₹173 Cr-5.72Q2 FY26rev ₹194 Cr-12.61Q3 FY26rev ₹207 Cr23.78Q4 FY26rev ₹238 Cr3.22Q1 FY27rev ₹304 Cr28.59Q2 FY27rev ₹341 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.

What management guided (1 FY-2027 call)
FY27 growth guidance withheld; management cited unpredictability. 7-ACA targeting March 2027 commercial batch; Cefiderocol facility by Dec 2026, product approval Q3 FY28. Exblifep partnerships expanding; Russia deal $178M estimated 10-year value.

Management continues to withhold formal FY27 growth guidance, citing unpredictability, so this print cannot be graded against a company-issued number. H1 FY27 revenue of ₹645.4 Cr is up 14.9% YoY, near the top of the 10-15% band the Street has been using as its working guidance, though a separate consensus FY27 growth forecast of 58.8% appears benchmarked against Orchid's pre-restatement (pre-merger) FY26 base rather than the like-for-like figures in this filing. Actual revenue of ₹341.3 Cr sits inside the ₹320-350 Cr range flagged in our pre-result preview; no public Street PAT estimate for the quarter could be found. No company press release accompanying this result was available to cross-check management's own framing of the quarter. The quarter also carried board actions flagged pre-result: the Exblifep licensing deal with Libra for Latin America (Oct 24) and a resolution for up to ₹600 Cr in fresh capital (Oct 20), alongside the Sep 24 listing of the merged entity's shares — none show up in revenue yet but mark the integration and funding track management is executing against.

  • W1

    Whether revenue growth holds near the 14-15% run-rate seen in Q1-Q2 FY27, given management still declines to issue formal FY27 guidance.

  • W2

    Use and progress of the up-to-₹600 Cr fundraising resolution approved Oct 20 — deleveraging vs. capex allocation.

  • W3

    Management-stated capacity milestones: 7-ACA commercial batch targeted March 2027 and the Cefiderocol facility targeted December 2026.

Converted from ₹ Lakh; Sep'25 comparatives are merger-restated (Dhanuka amalgamation, NCLT order, effective Jul 10 2026, appointed date Apr 1 2024) to revenue ₹298.5 Cr / PAT ₹(0.9) Cr — our stored year-ago figures (₹193.5 Cr / ₹-5.7 Cr, which match Q1 FY26 pre-restatement, not Q2) predate this restatement, so YoY here uses the PDF's own restated column; no exceptional items in any quarterly column (FY26's ₹7.33 Cr labour-code provision hit only the full year); consolidated PAT includes a ₹1.71 Cr associate (Orbion) profit share.

Informational and educational content only. Not investment advice.